Market Exclusive

LANDEC CORPORATION (NASDAQ:LNDC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

LANDEC CORPORATION (NASDAQ:LNDC) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective May 6, 2019, the Board of Directors of Landec Corporation (the “Company”) adopted an amendment to Section 2.5(a) of the Company’s By-Laws (the “Amendment”). The Amendment extends, to 5:00 p.m. PT on May 29, 2019, the date by which nominations of persons for election to the Board and/or business proposals may be submitted with respect to the 2019 Annual Meeting of Stockholders and included in the Company’s related proxy statement and form of proxy. A copy of the Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
LANDEC CORP \CA\ Exhibit
EX-3.1 2 ex-31.htm EXHIBIT 3.1 Exhibit EXHIBIT 3.1AMENDMENT NO 1 TOBY-LAWS OF LANDEC CORPORATIONSection 2.5(a) of the By-Laws of Landec Corporation is hereby amended to read in its entirety as follows:2.5.    Advance Notice of Stockholder Nominees and Other Stockholder Proposals. (a)    At an annual meeting of the stockholders,…
To view the full exhibit click here

About LANDEC CORPORATION (NASDAQ:LNDC)

Landec Corporation designs, develops, manufactures and sells a range of health and wellness products for food and biomaterials markets. The Company licenses technology applications to partners. The Company operates through three segments: Packaged Fresh Vegetables, Food Export and Biomaterials. The Packaged Fresh Vegetables segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. The Food Export segment is engaged in the purchase and sale of whole commodity fruit and vegetable products primarily to Asia. The Biomaterials segment sells products utilizing hyaluronan, a polysaccharide that is distributed in the extracellular matrix of connective tissues in both animals and humans, and non-hyaluronan (HA) products for medical use primarily in the ophthalmic, orthopedic and other markets.

Exit mobile version